Anti-hepatitis Agents

Random Miscellaneous Quiz

Can you name the Anti-hepatitis Agents?

Quiz not verified by Sporcle

How to Play
P-kinetics: Oral bioavailability increased with high-fat meal, decreased with antacid.
IFN α-2a/2b class
Contraindications: Hepatic decompensation, autoimmune dz, cardiac arrhythmia, pregnancy
Group P-kinetics: Pills once a day for a year or longer
IFN α-2b Class
Use: HBV treatment adults only
MOA: Serine protease inhibitors. Bind to inhibit HCV non-structural protein NS3
SE: Flu-like symptoms (fever, chills, myalgias, malaise). Neurotoxicity, myelosuppression, fatigue (chronic use). Transient hepatic enzyme elevation.
MOA: An adenosine analogue. Structurally similar to adefovir.
Use: HBV: Safer for pts w/ decompensated liver dz. For both adults & peds
P-kinetics: Higher rate of complete response & less resistance vs. adefovir
MOA: A prodrug (a guanosine nucleoside analogue). Phosphorylated by host cell enzymes; inhibits viral RNA-dependent polymerases.
P-kinetics: Slower clearance (less frequent dosing). Dosage adjustment is needed in renal dysfunction
Telbivudine (Tyzeka) Class
IFN alfacon-1 class
Tenofovir Class
Group MOA cont: Associated with mitochondrial DNA toxicity (by inhibiting DNA polymerase gamma)
Telaprevir Class
PEG-IFN α-2a Class
MOA: A prodrug of adefovir (adenosine analogue). Slows suppression of HBV DNA; least seroconversion
Use: Improve therapeutic response in pts (>18 yo) w/ HCV genotype 1 when combined w/ IFN/ribavirin
P-kinetics: Natural. SC or IM
MOA: A cytosine analogue
SE: Dose-dependent hemolytic anemia. Depression, fatigue, irritability, nausea, insomnia.
P-kinetics: Oral (TID). P450 substrates (potential rx interactions)
P-kinetics: Lipophilic (pivoxil) moiety enhances oral bioavailability.
MOA: A thymidine analog
Adefovir dipivoxil (Hepsera) Class
Group MOA cont. (3) Protein kinase (activated by dsRNA): phosphorylates/inhibits eIF-2, therefore blocking PRO synthesis
P-kinetics: Synthetic (consensus). SC
Entecavir (Baraclude) Class
Group MOA: 3 major enzymes are activated by IFN-JNK/STAT signaling pathway: (1) 2',5' oligo A synthase: produces 2'5' oligo A.
Drug MOA: PEG = polyethylene glycol
SE: Nephrotoxicity (at high doses). Potential mitochondrial DNA toxicity
P-kinetics:Oral bioavailability not affected by food. Emergence of resistance in long term use.
SE: HA, fatigue, nausea. Potential mitochondrial toxicity (lactic acidosis & hepatic steatosis)
P-kinetics: Clinical resistance is rare. Oral bioavailability decreased by food (taken w/ empty stomach). Renal elimination (serum concentration increased w/ altered kidney activit
Group MOA: Competively inhibit HBV DNA polymerase +/- incorporate into viral DNA causing chain termination. Phosphorylated to active forms intracellularly by cellular kinases.
SE: Increased pancreatitis in HIV/HBV pts. Emergence of resistance (mutations of DNA polymerase)
MOA: A guanisine analog. Inhibits all 3 functions of HBV RNA-dependent DNA polymerase (base priming, reverse transcription of the -strand, synthesis of the + strand of HBV DNA.
P-kinetics: Prolonged intracellular half-life in HBV (than in HIV). Rapid oral absorption; eliminated unchanged. Used at lower doses for hepatitis than for AIDS.
Group MOA cont. (2) Ribonuclease L (activated by 2'5' oligo A): degrades mRNA.
Use: Lamivudine-resistant HBV. Adults only
PEG-IFN α-2a/2b class
Boceprevir Class
Use: The most potent anti-HBV agent. Adults only
Use: Effective suppression of HBV DNA, normalization of ALT & reducing HBeAg. Adults only
Contraindications: Pts w/ uncorrected anemia, ESRD, preggo. Teratogenic: avoid pregnancy for > 6 mos thereafter
Lamivudine (3TC, Heptovir) Class
SE: Anemia, neutropenia, dysgeusia, skin rash (esp. telaprevir), increased QT intervals (telaprevir)

You're not logged in!

Compare scores with friends on all Sporcle quizzes.
Sign Up with Email
Log In

You Might Also Like...

Show Comments